**8. Conclusions**

The two described phenotypes should be used to classify the type of COVID-19 associated lung fibrosis in order to better define the evolution of these conditions and determine the appropriate treatment strategy and the timing of lung transplant evaluation and listing. With additional data in this rapidly evolving field, the two phenotypes may be defined more clearly and the multiple treatment options can be used optimally based on an increasing body of evidence. Long-term fibrotic complications remain a major concern contributing to morbidity and mortality.

**Author Contributions:** Conceptualization, R.H. and M.M.S.; methodology, R.H. and M.M.S.; writingoriginal draft preparation R.H.; writing-review and editing M.M.S.; supervision M.M.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** This study did not require ethical approval.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.
